Forward–Looking Statements

This presentation contains, and any accompanying oral presentation would no doubt contain, forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, regarding us (Biocept, Inc.) and our business. Forward-looking statements include all statements that are not historical facts and generally can be identified by terms such as anticipates, believes, could, estimates, expects, intends, may, plans, potential, predicts, projects, should, will, would, or the negative of those terms and similar expressions.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For details about these risks, please see our SEC filings.

All forward looking statements contained in this presentation speak only as of the date hereof, and except as required by law, we assume no obligation to update these forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.
This presentation highlights basic information about us and the offering to which this communication relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our common stock.

We have filed a registration statement (including a prospectus, which currently is in preliminary form) with the US Securities and Exchange Commission for the offering to which this presentation relates. The registration statement has not yet become effective. Before you invest, you should read the preliminary prospectus in the registration statement (including the risk factors described therein) and other documents we have filed with the SEC for more complete information about us and the offering.

You may access these documents for free by visiting EDGAR on the SEC website at http://www.sec.gov

The preliminary prospectus, dated January 21, 2015, is available on the SEC Web site at: http://www.sec.gov/Archives/edgar/data/1044378/000095012315000039/bioc-s1a_20140930.htm

Alternatively, we or any underwriter participating in the offering will arrange to send you the preliminary prospectus and, when available, the final prospectus and/or any supplements thereto if you contact Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, telephone: 212-813-1010, e-mail: prospectus@aegiscap.com
<table>
<thead>
<tr>
<th><strong>Issuer</strong></th>
<th>Biocept, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exchange/Ticker</strong></td>
<td>NASDAQ Capital Market / BIOC</td>
</tr>
<tr>
<td><strong>Offering Size</strong></td>
<td>Approx. $15,000,000 of Common Stock (100% Primary)</td>
</tr>
<tr>
<td><strong>Over-Allotment</strong></td>
<td>15% (100% Primary)</td>
</tr>
</tbody>
</table>
| **Use of Proceeds** | • Sales and marketing for test offerings  
                          • Assay development and validation  
                          • Automation and scale up |
| **Joint Book-Runners** | • Aegis Capital Corp. and Feltl and Company |
Biocept’s Liquid Biopsy Solution

Answering an Unmet Medical Need

*Do I qualify for this drug?*

*Does my treatment need to be changed?*

The Right Therapy for the Right Patient at the Right Time
**Business Overview**

- CLIA facility in San Diego, CA
- Genomic test results sent to physicians
- R & D, test kits manufactured and samples analyzed
Investment Highlights

*Commercial stage cancer diagnostics company with groundbreaking technology platform utilizing a simple blood test*

**OncoCEE™:** captures circulating tumor cells (CTCs)
**CEE-Selector™:** enhanced sensitivity for genomic mutation analysis
Commercialized tests for breast, gastric and non-small cell lung cancer
Test pipeline focused on solid tumor biomarkers in lung, breast, colorectal, prostate and melanoma
Established, certified and scalable CLIA lab
Clear path to market penetration
Established research collaborations and strategic partnerships
# Biocept Executive Team

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Experience and Achievements</th>
</tr>
</thead>
</table>
| David Hale          | Chairman                  | - CEO of Hale BioPharma Ventures with over 36 years as a life sciences sector leader  
- Chairman (current or former) of Santarus (acquired by Salix), Conatus, Micromet (acquired by Amgen), and SkinMedica (acquired by Allergan)  
- CEO of Hybritech (acquired by Lilly), Gensia (acquired by Teva)                                                                                                                                       |
| Michael Nall        | President and CEO         | - More than 25 years in healthcare sales, marketing and commercial operations  
- 16 years in cancer diagnostics and genomics  
- Most recently General Manager N. American Sales and Marketing for Clarient—a GE Healthcare Company                                                                                                                                                               |
| William Kachioff    | SVP, Finance and CFO      | - 25 years life sciences industry experience  
- 15 years of experience in public company finance  
- Abbott Labs, Cutera, Coulter Pharmaceutical, Althea, Vivus  
- Diverse finance and operations management experience                                                                                                                                                                                                         |
| Lyle Arnold, Ph.D.  | SVP, R&D and CSO          | - Senior R&D Leadership at Gen-Probe, Incyte Genomics, Genta  
- Founder/ Co-founder Oasis Biosciences, Molecular Biosystems, Aegea Biotechnologies  
- Former faculty member, UCSD School of Medicine and member, UCSD Cancer Center  
- 40 issued US and more than 140 issued and pending patents worldwide                                                                                                                                                                                      |
| Veena Singh, MD     | SVP and Sr. Medical Director | - Board certified molecular pathologist, UCSD, Cedars Sinai trained  
- Numerous publications, serves on CAP committees for oncology biomarkers  
- Most recently Medical Director – bioTheranostics                                                                                                                                                                                                             |
| Raaj Trivedi        | VP Commercial Operations  | - More than 15 years in the biotechnology and diagnostics industry  
- Served as VP of Marketing and VP of Business Development at Clarient – a GE Healthcare Company  
- Life Technologies Commercial Leader for Oncomine Biomarker Discovery Panel                                                                                                                                                                                      |
Multifaceted Growth Strategy

Sales and Marketing Investment
- Physician and hospital market for treatment decisions
- Biopharma and research services
- Collaboration and partnership agreements

Research and Development
- Clinical utility studies
- Validation of test in pipeline
- Enhanced technology

Operational Efficiency
- Investment in automation
- Optimize capacity of infrastructure
2014 Accomplishments

- Appointed Veena Singh as SVP and Senior Medical Director
- Appointed Raaj Trivedi as Vice President - Commercial Operations
- Recruited a national sales team to support commercialization
- Implemented reimbursement and managed care plan
- Gained coverage for approx. 19M patients in large PPO network
- Awarded additional issued patents in Europe, China and S. Korea
- Gained and expanded collaborations with MD Anderson, Rosetta and Insight
- Launched Clinical Research Services in Circulating Tumor DNA
- Secured $10 Million Term Loan Facility With Oxford Finance LLC
- Increased menu of testing:
  
  ER in breast cancer; ALK, ROS1 and T790M/EGFR in NSCLC and HER2 in gastric cancer.
Target Market

925,030
Newly Diagnosed Cancers

8,009,272
Living with Cancer

“...liquid biopsies have a multi-billion dollar market potential that could eventually exceed $10B”

Cowen and Company Liquid Biopsy Industry Report, November, 2014

Profiling Newly Diagnosed Cancers

Monitoring Patients Living with Cancer

Limitations of Tissue Biopsy

Cancer is a heterogeneous disease
- Molecular properties differ within a tumor
- Primary tumor biopsy may not reflect current disease condition
- Therapy causes changes in tumor cells

Biopsy is invasive
- May not be feasible based on patient condition or tumor accessibility
- Impractical for periodic monitoring for progression / recurrence

Biopsy tissue is limited
- Greater demand due to molecular profiling
- Surgery is costly

Liquid Biopsy Addresses Limitations in Standard of Care
Reducing Healthcare Costs

Average cost of biopsy: $14,634\(^1\)

Average cost when adverse events such as collapsed lung, bleeding or pneumonia occurred was 4X higher\(^1\)

**Average cost of blood draw:**

*between $6 and $167*\(^2\)

*... potentially saving our healthcare system billions*

---


\(^2\)http://clearhealthcosts.com/blog/2012/12/how-much-does-a-blood-test-cost-it-could-be-16-or-117/
New Molecular Paradigm

Liquid biopsy (CTCs and ctDNA) - surrogate for tumor tissue biopsy
Repeatable for monitoring patient response to treatment
Provides tumor biomarker status when tissue is not available
Reduce false negatives attributable to heterogeneity
Detect metastasis, recurrence and biomarker conversion
Qualify more patients for targeted therapies

66% of researchers say analysis of CTCs will be the standard of care by 2017*

*CTC industry overview – Hanson and Wade  2013
Platform Overview

Plasma – ctDNA

Buffy Coat – CTCs

Red Blood Cells

ctDNA Analysis

- B-Raf
  - ZELBORAF® (vemurafenib)

- K-Ras
  - ERBITUX® (cetuximab)
  - VECTIBIX® (panitumumab)

- EGFR
  - TARCEVA® (erlotinib)
  - IRESSA® (gefitinib)

CTC Analysis

- HER2
  - HERCEPTIN® (trastuzumab)

- ALK
  - XALKORI® (crizotinib)

- ROS1
  - XALKORI® (crizotinib)
Circulating Tumor Cells (CTCs)

- Detection, enumeration and cytogenetic/molecular analysis in blood or bone marrow samples

CTC Capture

ICC for Protein

FISH for Genes
Patented arrangement of posts optimized for ultra-sensitive rare cell capture
Mounted on glass slide and transparent, enabling direct microscopic visualization of captured CTCs
Multiple assays can be performed on captured CTCs
Cells can be released for further analysis, including CEE-Selector mutation analysis, and is intended for next generation sequencing at Biocept or with industry partners
# OncoCEE™

**A New Standard in Oncology Diagnostics**

<table>
<thead>
<tr>
<th>OncoCEE™ Platform</th>
<th>CellSearch (J&amp;J) Platform</th>
</tr>
</thead>
</table>
| Proprietary CTC antibody capture cocktail  
Not limited to “traditional” epithelial CTCs  
Captures more CTCs | • Single capture antibody  
• Limited to “traditional” epithelial CTCs |
| Immediate post-capture biomarker analysis | • No biomarker analysis offered under FDA clearance |
| Tests for Breast, Gastric, Lung cancers  
with Colon, Prostate, Melanoma planned | • Only available for Breast, Colon, Prostate |
Published CTC Enumeration Comparison*

Traditional Definition of CTCs (CK+, CD45-, DAPI+)

*Pecot et al, Cancer Discovery, Dec. 2011
Biocept Technology Detects More CTCs

- Traditional definition of CTC
- Biocept captures more of these due to antibody cocktail and microfluidic channel design

- >50% of HER2 Positive cells are CK negative* and are considered to be a tumor cell
- CK negative cells missed by competitors
- Biocept captures these types of cells

Ground-Breaking CEE-Selector Platform

Plasma – ctDNA
Buffy Coat – CTCs
Red Blood Cells

CTCs and cell free ctDNA for Genomic Testing

- **B-Raf**
  - ZELBORAF® (vemurafenib)

- **K-Ras**
  - ERBITUX® (cetuximab) & VECTIBIX® (panitumumab)

- **EGFR**
  - TARCEVA® (erlotinib) & IRESSA® (gefitinib)

CTC Capture
Advantages of CEE-Selector™ Platform

Mutation determination sensitivity 10-100x better than competing platforms*

Allows for both CTC and cell free ctDNA analysis
Detects 1 mutation out of >10,000 normal DNA
Works with various nucleic acid targets (DNA and RNA)
Compatible with sequencing and PCR instruments
Multiplexing reduces costs and enhances reimbursement
Potential applications in all stages of cancer

* Biocept internal data
## OncoCEE™ Product Profiles

*Italicized and underlined biomarkers are currently available to Biocept customers*

<table>
<thead>
<tr>
<th>Product</th>
<th>Tumor Type</th>
<th>OncoCEE™ CTC</th>
<th>CEE-Selector™</th>
</tr>
</thead>
<tbody>
<tr>
<td>OncoCEE-BR™</td>
<td>Breast</td>
<td><em>Enumeration of CTCs, HER2, ER, PR</em></td>
<td>ER mutation</td>
</tr>
<tr>
<td>OncoCEE-GA™</td>
<td>Gastric</td>
<td><em>Enumeration of CTCs, HER2</em></td>
<td>Currently no clinically actionable mutations identified</td>
</tr>
<tr>
<td>OncoCEE-LU™</td>
<td>Lung</td>
<td><em>Enumeration of CTCs, ALK, ROS1, MET</em></td>
<td><em>EGFR, K-ras, B-raf mutations, ALK mutations</em></td>
</tr>
<tr>
<td>OncoCEE-CR™</td>
<td>Colon</td>
<td><em>Enumeration of CTCs, EGFR</em></td>
<td>K-ras, B-raf mutations</td>
</tr>
<tr>
<td>OncoCEE-PR™</td>
<td>Prostate</td>
<td><em>Enumeration of CTCs, AR, and PTEN deletion (blood or bone marrow)</em></td>
<td>Currently no clinically actionable mutations identified</td>
</tr>
<tr>
<td>OncoCEE-ME™</td>
<td>Melanoma</td>
<td><em>Enumeration of CTCs</em></td>
<td>B-raf and N-ras mutations</td>
</tr>
</tbody>
</table>
Established CLIA Facility

CLIA inspected and certified
CAP accredited for high complexity testing
Manufacturing and lab operations in place
Scalable for future growth
Laboratory information system with client portal
Adjacent clinical development and research facility
Automation solutions in place
Targeted Commercialization Strategy

- Raise awareness of the value of CTCs and ctDNA
- Drive OncoCEE adoption
  - Market directly to oncologists and other physicians
  - Develop key opinion leader speakers
- Build relationships with patient advocacy groups
- Publish studies with major cancer centers
- Participate in medical meetings / symposia
- Deepen payor relationships and expand reimbursement coverage
- Expand strategic partnerships with pharma and biotech for personalized diagnostics
Driving Adoption for Growth

Salesforce Plan

- Head of sales and marketing
- Regionally based sales team
- Sales team for pharma
- Managed care expert
- Internal marketing
- Leverage partner sales forces
Increasing Adoption

Commercial Samples Per Quarter

Average reimbursement per sample YTD: $1,062
Revenue and Reimbursement

Utilize established CPT codes for coverage today
- Medicare covers analysis component of testing
- Select private payors cover CTC capture, enumeration and analysis
- Seeking Medicare coverage for capture and enumeration

Diversified revenue streams
- Grow clinical trial business and other fee for service channels
- Establish new revenue sources through partnerships

Perform clinical utility study against tissue biopsy
- Health economics impact
- Goal is to show improved outcomes with reduced costs
## Clinical Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Columbia** | - Patients with ER positive metastatic and primary biopsy  
- Correlation of ER status – Biocept OncoCEE BR™ with metastatic and primary biopsy  
- Accepted for publication – pending review |
| **Dana-Farber** | - Metastatic Breast Cancer patients with HER2 negative primary biopsy  
- CTC HER2 positive patients, as detected with OncoCEE BR, placed on Herceptin  
- 22% of patients were Her2 positive on CTCs but negative on tissue  
- Sponsored by Genentech, Komen Foundation |
| **MD Anderson** | - Published in Cancer Medicine – April 2013  
- Recently diagnosed breast cancer patients  
- 15% of CTC and 28% of DTCs have HER2 discordance with primary tumor  
- Current Ovarian study – CTCs as predictive of outcomes |
| **Other studies** | - Four additional peer reviewed published studies validating technology  
- Additional pending studies with collaborators  
- Planned study in Non Small Cell Lung Cancer |
CEE-Sure™
Stability
Transport Tube
Patent pending

Multiple issued patents in US, EU, China and Korea

OncoCEE™
Chemistry: Antibody Cocktail
Patent pending

Two US and associated foreign patents pending for capture; one US and associated foreign patents pending for detection

CEE-Selector™
Mutation Analysis
Patent pending

One US and associated foreign patents pending
### Current Capital Structure
(as of 12/31/14 - excluding shares in this offering)

<table>
<thead>
<tr>
<th>Shares Outstanding</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Common Stock</strong></td>
<td>4,449,603</td>
</tr>
<tr>
<td><strong>Equity Awards</strong>¹</td>
<td>1,157,812</td>
</tr>
<tr>
<td><strong>Warrants</strong>²</td>
<td>610,774</td>
</tr>
<tr>
<td><strong>Fully Diluted Shares Outstanding</strong></td>
<td>6,218,189</td>
</tr>
</tbody>
</table>

¹ Average option exercise price of $6.29
² Average exercise price is $9.47/share
Leading Cancer Diagnostic Companies

- **Foundation Medicine**: Sold 56% to Roche for $1.2B
- **NeoGenomics Laboratories**: Market cap $241M*
- **Clariant**: Sold to GE Healthcare $576M
- **Myriad**: Market cap $2.84B*
- **Genomic Health**: Market Cap $1.043B*
- **Genoptix Medical Laboratory**: Sold to Novartis - $470M

*Market Cap close of market – January 16, 2014*
**Investment Highlights**

*Commercial stage cancer diagnostics company with groundbreaking technology platform utilizing a simple blood test*

**OncoCEE™**: captures circulating tumor cells (CTCs)

**CEE-Selector™**: enhanced sensitivity genomic mutation analysis

Commercialized tests for breast, gastric and certain lung cancers

Test pipeline focused on solid tumor biomarkers in lung, breast, colorectal, prostate and melanoma

Established, certified and scalable CLIA lab

Clear path to market penetration

Established research collaborations and strategic partnerships